EcoDrugPlus

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMMNG00015018022
Gene Symbol: MKNK1
3 Cross references
167 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSMMNG00015003637
Gene Symbol: MKNK2
3 Cross references
220 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSMMNG00015004577
Gene Symbol: MCL1
3 Cross references
238 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSMMNG00015020796
Gene Symbol: MDM2
3 Cross references
262 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMMNG00015007208
Gene Symbol: MET
3 Cross references
211 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSMMNG00015007116
Gene Symbol: MPL
3 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSMMNG00015006612
Gene Symbol: MLST8
3 Cross references
201 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSMMNG00015003525
Gene Symbol: NQO1
3 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSMMNG00015021151
Gene Symbol: NOX4
3 Cross references
151 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSMMNG00015007306
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSMMNG00015011499
Gene Symbol: NPC1L1
3 Cross references
189 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMMNG00015009784
Gene Symbol: PIM1
3 Cross references
244 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).